PARIS, November 26, 2024
Biolevate, a Paris-based startup specializing in AI-powered solutions for healthcare, has secured €6 million in seed funding. The round was led by EQT Ventures, with participation from bpifrance and several angel investors. The funding will be used to enhance the company’s proprietary platform, ELISE, and expand its team with top-tier talent.
Revolutionizing Medical Writing
Founded by Joël Belafa and Nathan Chen, Biolevate addresses the inefficiencies in medical writing, a critical yet time-intensive component in healthcare innovation. The company’s AI-driven platform, ELISE, leverages Natural Language Processing (NLP), Graph Neural Networks (GNN), and Computer Vision to streamline the creation, validation, and management of regulatory documents.
ELISE provides:
• Real-time collaborative writing: Facilitates compliance and literature review with instant suggestions and edits.
• Automated data analysis: Reduces manual effort, increases accuracy, and ensures consistency in documentation.
• Support for complex data workflows: Enhances risk assessments and anomaly detection to expedite medical R&D processes.
Strategic Growth
Biolevate’s inclusion in Station F’s Future 40 list underscores its innovation in healthcare technology. The fresh capital will enable the company to:
• Scale ELISE’s capabilities across pharmaceutical, cosmetic, and medical device sectors.
• Build a robust team of AI and healthcare experts.
• Strengthen its global presence and expand market access solutions.
CEO Vision
CEO Joël Belafa remarked:
“Our mission is to use AI to accelerate the development of life-saving therapies, ensuring faster availability for patients. Biolevate aims to address longstanding inefficiencies in medical writing, a challenge that delays innovation and impacts public health.”
Industry Impact
With pharmaceutical R&D spending doubling in the last decade, Biolevate’s solutions are poised to address a global workforce shortage in medical writing. By automating processes and integrating cutting-edge AI technologies, the company reduces costs, accelerates time-to-market, and ensures regulatory compliance.
Julien Hobeika, Partner at EQT Ventures, stated:
“Biolevate’s platform transforms medical documentation into a seamless and effective process, driving scientific breakthroughs that benefit society.”
Future Prospects
Biolevate plans to expand ELISE’s functionality to support drug discovery and other healthcare applications. The company is exploring opportunities to commercialize its platform as a service for broader industries and as individual APIs.
For more information, visit biolevate.com.
Media Contact:
Email: [email protected]
Location: Paris, France
